A multi centre, single-arm, prospective interventional study to evaluate the therapeutic effect of oral nutritional supplement on improving malnutrition and sarcopenia in chronic liver disease (CLD) patients.

Dr Reddys Laboratories0 个研究点目标入组 0 人开始时间: 待定最近更新: 2023年6月26日

试验速览

暂无简介。

•1. Age >= 18 years to <= 65 yearsâ?? adults (male or female diagnosed with chronic liver disease) with clinically diagnosed chronic liver disease
•2. Malnutrition screening tool i.e., royal free hospital malnutrition tool (See below for details)
•3. No gastrointestinal bleeding for at least 4 weeks.
•4. No clinical evidence of infection, comorbidities diabetes mellitus.
•5. Alcoholic patients who have been abstinent for at least 3 months.
•6. No sepsis for less than 4 weeks
•7. Hepatocellular carcinoma (HCC) patients can be included.
•8. Hepatic Encephalopathy (HE) less than grade three
•9. Patients with creatinine less than 1.5mg/dl
•10. Patients who are waiting for liver transplant.

•1. Allergy or contraindications to protein, milk, nuts, or any of the ingredients of the nutritional supplement.
•2. All cancers patients except Hepatocellular carcinoma to be excluded.
•3. Presence of conditions that would affect normal response to repletion of protein and calories, such as gastrointestinal disorders including inflammatory bowel disease.
•4. Patients not able to tolerate the oral nutritional supplements (ONS).
•5. Pregnant and lactating women.

发起方

Dr Reddys Laboratories